Abstract
The widespread availability of functional imaging in clinical practice has revolutionized the care (staging, response assessment, surveillance) of patients with lymphoma. Using positron emission tomography/computed tomography (PET/CT) with fludeoxyglucose F 18 (FDG), the potential exists for prognostic risk stratification and therapeutic adjustment. This review focuses on personalization of therapy using these 2 modalities in 2 lymphoma subtypes: diffuse large B-cell lymphoma and Hodgkin lymphoma.
| Original language | English |
|---|---|
| Pages (from-to) | 57-65 |
| Number of pages | 9 |
| Journal | PET Clinics |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2012 |
Keywords
- Diffuse large B-cell lymphoma
- Hodgkin lymphoma
- PET/CT
- Positron emission tomography (PET)
Fingerprint
Dive into the research topics of 'Role of positron emission tomography with fludeoxyglucose F 18 in personalization of therapy in patients with lymphoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver